 The FDA has finally approved AVEO Pharmaceuticals Incs NASDAQ: AVEO tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The label covers relapsed or refractory renal cell carcinoma who have received two or more prior systemic therapies. 